TAKEDA PHARMACEUTICAL COMPANY LIMITED |
Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
| 4’130 JPY | -0.19% |
|
+0.02% | +1.87% |
| 16.05. | Takeda Kanada schließt LOI-Phase für Cytomegalovirus-Behandlung nach Transplantation ab | MT |
| 15.05. | Dengue-Impfstoff von Takeda Pharmaceutical erhält Präqualifikation der WHO | MT |
Kurzporträt
- Verkauf von Arzneimitteln und Verbraucherpflegeprodukten;
- Dienstleistungen.
Der Nettoumsatz verteilt sich geographisch wie folgt: Japan (17,5%), Asien (5%), die Vereinigten Staaten (49%), Europa und Kanada (20,8%), Lateinamerika (3,8%), Russland und GUS (1,8%) und Sonstige (2,1%).
Mitarbeiterzahl: 49 095
Umsatz nach Geschäftsbereich
| JPY in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
|---|---|---|---|---|---|
Gastrointestinal
27,2
%
| 875 685 | 24,5 % | 1 094 541 | 27,2 % | +24.99% |
Plasma Derivatives (Immune)
16,8
%
| 506 951 | 14,2 % | 678 443 | 16,8 % | +33.83% |
Neuroscience
15,8
%
| 482 294 | 13,5 % | 637 711 | 15,8 % | +32.22% |
Other
11,3
%
| 624 150 | 17,5 % | 454 598 | 11,3 % | -27.17% |
Oncology
10,9
%
| 468 730 | 13,1 % | 438 742 | 10,9 % | -6.40% |
Rare Genetic Disease and Others
10,4
%
| - | - | 418 724 | 10,4 % | - |
Rare Hematology
7,6
%
| 283 689 | 7,9 % | 304 718 | 7,6 % | +7.41% |
Umsatz je Region
| JPY in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
|---|---|---|---|---|---|
United States
52,2
%
| 1 714 421 | 48,0 % | 2 103 772 | 52,2 % | +22.71% |
Europe and Canada
20,9
%
| 739 168 | 20,7 % | 842 668 | 20,9 % | +14.00% |
Japan
12,7
%
| 658 983 | 18,5 % | 512 043 | 12,7 % | -22.30% |
Asia
5,6
%
| 196 964 | 5,5 % | 225 007 | 5,6 % | +14.24% |
Latin America
4,0
%
| 128 467 | 3,6 % | 160 375 | 4,0 % | +24.84% |
Other
2,4
%
| 68 945 | 1,9 % | 95 182 | 2,4 % | +38.05% |
Russia / Commonwealth of Independent States
2,2
%
| 62 057 | 1,7 % | 88 431 | 2,2 % | +42.50% |
Manager
| Manager | Titel | Alter | Seit |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 01.04.14 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 01.02.22 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 01.01.12 |
| Chief Tech/Sci/R&D Officer | 69 | 01.04.15 | |
Andrew Plump
CTO | Chief Tech/Sci/R&D Officer | 58 | 01.02.15 |
Norimasa Takeda
CMP | Compliance Officer | - | - |
| Director/Board Member | 53 | 01.01.15 | |
Haruhiko Hirate
IRO | Public Communications Contact | - | - |
Takashi Okubo
IRO | Public Communications Contact | - | - |
| Investor Relations Contact | - | 01.06.11 |
Aufsichtsräte
| Aufsichtsräte | Titel | Alter | Seit |
|---|---|---|---|
| Director/Board Member | 71 | 01.06.16 | |
Ian Clark
BRD | Director/Board Member | 62 | 01.01.19 |
Steven Gillis
BRD | Director/Board Member | 71 | 01.01.19 |
John Maraganore
BRD | Director/Board Member | 60 | 01.06.22 |
Emiko Higashi
BRD | Director/Board Member | 64 | 01.06.16 |
Michel Orsinger
BRD | Director/Board Member | 66 | 01.06.16 |
Christophe Weber
CEO | Chief Executive Officer | 57 | 01.04.14 |
| Director/Board Member | 53 | 01.01.15 | |
Kimberly Reed
BRD | Director/Board Member | 53 | 01.06.22 |
Miki Tsusaka
BRD | Director/Board Member | 61 | 01.04.23 |
Anteilsklasse
| Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
|---|---|---|---|---|---|
| Aktie A | 0 | 1 582 418 725 | 1 568 419 964 ( 99,12 %) | 13 405 261 ( 0,8471 %) | 99,12 % |
Unternehmensbesitz
| Name | Aktien | % | Bewertung |
|---|---|---|---|
| 7 511 300 | 0,47% | 198 229 742 $ | |
HILLEVAX, INC. 13,53% | 6 724 000 | 13,53% | 80 822 480 $ |
DENALI THERAPEUTICS INC. 2,96% | 4 214 559 | 2,96% | 63 049 803 $ |
| 2 204 000 | 7,21% | 32 619 178 $ | |
OVID THERAPEUTICS INC. 12,42% | 8 781 996 | 12,42% | 26 258 168 $ |
| 2 790 480 | 4,77% | 25 393 368 $ | |
NOILE-IMMUNE BIOTECH INC. 18,76% | 8 119 800 | 18,76% | 8 358 928 $ |
WAVE LIFE SCIENCES LTD. 0,90% | 1 096 892 | 0,90% | 5 199 268 $ |
Unternehmenskontakt
Takeda Pharmaceutical Co., Ltd.
4-1-1 Dosho-machi Chuo-Ku
540-8645, Osaka
+81 3 3278 2111
http://www.takeda.co.jp
Konzerngesellschaften
| Name | Kategorie und Branche |
|---|---|
Shire Biotech India Pvt Ltd.
| |
Takeda Belgium NV
 Takeda Belgium NV Medical DistributorsDistribution Services Founded in 1835, Takeda Belgium NV is a subsidiary of Takeda Pharmaceutical Co., Ltd. The company is based in Zaventem, Belgium and focuses on providing better healthcare solutions for their patients. Takeda Belgium's mission is centered around the question of how they can do more for their patients. |
Medical Distributors
|
Takeda Pharmaceuticals U.S.A., Inc.
 Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. |
Pharmaceuticals: Major
|
Shire Ireland Finance Trading Ltd.
| |
Shire Biotech UK Holdings Ltd.
 Shire Biotech UK Holdings Ltd. Financial ConglomeratesFinance Part of Takeda Pharmaceutical Co., Ltd., Shire Biotech UK Holdings Ltd. is an investment holding company. Shire Biotech UK Holdings Ltd. is based in London, UK. Founded in 2017, Shire Biotech UK Holdings functions as an investment holding company. |
Financial Conglomerates
|
Takeda A/S
 Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. |
Financial Conglomerates
|
Takeda Pharmaceuticals International AG
 Takeda Pharmaceuticals International AG Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals International GmbH develops, manufactures, and distributes pharmaceutical products. It offers medicines in therapeutic areas, such as, cardiovascular and metabolic, oncology, central nervous system, respiratory and immunology, general medicine, and vaccines. The firm also provides packaging, development, contract manufacturing and quality control services. Takeda Pharmaceuticals International was founded in 1874 and is headquartered in Zurich, Switzerland. |
Pharmaceuticals: Major
|
Takeda Manufacturing Austria AG
 Takeda Manufacturing Austria AG Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Takeda Manufacturing Austria AG manufactures and supplies vital medicines and medical devices. The company is based in Vienna, Austria. |
Pharmaceuticals: Major
|
Takeda GmbH
 Takeda GmbH Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Takeda GmbH is a German pharmaceutical company that manufactures pharmaceutical products. The company is based in Konstanz, Germany. The CEOs are Wolfgang Eck, Uwe Hoffmeister, Roland Kurney. The company was founded in 1873. |
Pharmaceuticals: Major
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
| % 1. Jan. | Kap. | |
|---|---|---|
| +1.87% | 41.69 Mrd. | |
| +32.09% | 693 Mrd. | |
| +29.39% | 584 Mrd. | |
| -1.34% | 372 Mrd. | |
| +20.34% | 332 Mrd. | |
| +7.39% | 294 Mrd. | |
| +14.25% | 239 Mrd. | |
| -3.03% | 211 Mrd. | |
| +10.02% | 210 Mrd. | |
| +8.49% | 168 Mrd. |
- Börse
- Aktien
- 853849 Aktie
- Unternehmen Takeda Pharmaceutical Company Limited
